Ann K Wittkowsky1, Emily Beth Devine. 1. School of Pharmacy, University of Washington, Seattle, Washington, USA. akwitt@u.washington.edu
Abstract
STUDY OBJECTIVE: To determine the frequency and the specific causes of over- and underanticoagulation in patients who receive warfarin therapy and are managed in an anticoagulation clinic. DESIGN: Retrospective medical record review. SETTING: University-affiliated anticoagulation clinic. SUBJECTS: One thousand twenty patients (mean age 60.2 yrs [range 17-84 yrs]) receiving warfarin therapy during a 1-year index period. MEASUREMENTS AND MAIN RESULTS: Of 12,897 international normalized ratios (INRs) evaluated, 6642 (51.5%) were within range and 8525 (66.1%) were within 0.2 INR units of range. Among 2881 out-of-range INRs below 2.0, the most common cause of underanticoagulation was indeterminate (856, 29.7%). Response to previous change in dosage (16.4%), noncompliance or dosing errors (16.3%), and initiation of therapy (15.6%) were other common causes of underanticoagulation. Changes in drugs, medical condition, dietary vitamin K intake, alcohol use, and activity level, in combination, accounted for only 15.1% of INRs below 2.0. Among 603 out-of-range INRs greater than 4.0, the most common cause of overanticoagulation was indeterminate (43.0%). Changes in medical condition (15.9%), response to a previous change in warfarin dosage (11.4%), and interactions with prescription drugs (7.3%) were other common causes of overanticoagulation. In combination, noncompliance or dosing errors, initiation of therapy, and change in dietary vitamin K intake accounted for only 15.4% of INR values above 4.0. CONCLUSION: Out-of-range INRs are encountered frequently during warfarin therapy as a result of changes in numerous factors. Despite extensive evaluation of potential causes of over- and underanticoagulation, a specific cause commonly cannot be determined.
STUDY OBJECTIVE: To determine the frequency and the specific causes of over- and underanticoagulation in patients who receive warfarin therapy and are managed in an anticoagulation clinic. DESIGN: Retrospective medical record review. SETTING: University-affiliated anticoagulation clinic. SUBJECTS: One thousand twenty patients (mean age 60.2 yrs [range 17-84 yrs]) receiving warfarin therapy during a 1-year index period. MEASUREMENTS AND MAIN RESULTS: Of 12,897 international normalized ratios (INRs) evaluated, 6642 (51.5%) were within range and 8525 (66.1%) were within 0.2 INR units of range. Among 2881 out-of-range INRs below 2.0, the most common cause of underanticoagulation was indeterminate (856, 29.7%). Response to previous change in dosage (16.4%), noncompliance or dosing errors (16.3%), and initiation of therapy (15.6%) were other common causes of underanticoagulation. Changes in drugs, medical condition, dietary vitamin K intake, alcohol use, and activity level, in combination, accounted for only 15.1% of INRs below 2.0. Among 603 out-of-range INRs greater than 4.0, the most common cause of overanticoagulation was indeterminate (43.0%). Changes in medical condition (15.9%), response to a previous change in warfarin dosage (11.4%), and interactions with prescription drugs (7.3%) were other common causes of overanticoagulation. In combination, noncompliance or dosing errors, initiation of therapy, and change in dietary vitamin K intake accounted for only 15.4% of INR values above 4.0. CONCLUSION: Out-of-range INRs are encountered frequently during warfarin therapy as a result of changes in numerous factors. Despite extensive evaluation of potential causes of over- and underanticoagulation, a specific cause commonly cannot be determined.
Authors: Hussain A Isma'eel; George E Sakr; Robert H Habib; Mohamad Musbah Almedawar; Nathalie K Zgheib; Imad H Elhajj Journal: Eur J Clin Pharmacol Date: 2013-12-03 Impact factor: 2.953
Authors: Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton Journal: Pharmacogenomics Date: 2008-05 Impact factor: 2.533
Authors: Larisa H Cavallari; Jonathan L Aston; Kathryn M Momary; Nancy L Shapiro; Shitalben R Patel; Edith A Nutescu Journal: J Thromb Thrombolysis Date: 2008-06-19 Impact factor: 2.300
Authors: Alec B Platt; A Russell Localio; Colleen M Brensinger; Dean G Cruess; Jason D Christie; Robert Gross; Catherine S Parker; Maureen Price; Joshua P Metlay; Abigail Cohen; Craig W Newcomb; Brian L Strom; Mitchell S Laskin; Stephen E Kimmel Journal: Pharmacoepidemiol Drug Saf Date: 2008-09 Impact factor: 2.890
Authors: Dean G Cruess; A Russell Localio; Alec B Platt; Colleen M Brensinger; Jason D Christie; Robert Gross; Catherine S Parker; Maureen Price; Joshua P Metlay; Abigail Cohen; Craig W Newcomb; Brian L Strom; Stephen E Kimmel Journal: Int J Behav Med Date: 2010-03
Authors: Martin H Prins; Alexia Marrel; Paulo Carita; David Anderson; Marie-Germaine Bousser; Harry Crijns; Silla Consoli; Benoit Arnould Journal: Health Qual Life Outcomes Date: 2009-02-06 Impact factor: 3.186